key: cord-0849925-9elso0sx
authors: Li, Shuanglei; Xiong, Jing; Du, Zhongtao; Lai, Wei; Ma, Xinhua; Feng, Zhichun; Shi, Yuan; Hong, Xiaoyang; Chen, Yundai
title: Extracorporeal membrane oxygenation (ECMO) for critically ill patients with coronavirus disease 2019 (COVID‐19): A retrospective cohort study
date: 2021-07-22
journal: J Card Surg
DOI: 10.1111/jocs.15833
sha: 355babdff6b6caeaca652110f9d913538e58a322
doc_id: 849925
cord_uid: 9elso0sx

PURPOSE: The role of extracorporeal membrane oxygenatio (ECMO) for rescue therapy of respiratory failure in critically ill coronavirus disease 2019 (COVID‐19) patients remains controversial. We aimed to evaluate the clinical outcomes of ECMO in the treatment of COVID‐19 compared with conventional ventilation support. METHODS: In this retrospective cohort study, data were collected on extremely critical patients with COVID‐19 from January 2020 to March 2020 in intensive care unit of a hospital in charge by national rescue team in Wuhan, China, the epicenter of pandemic. Patients were classified into the ECMO group and the conventional ventilation non‐ECMO group. Clinical characteristics, technical characteristics, laboratory results, mortality, and complications of the two groups were analyzed. RESULTS: 88 patients with extremely critical COVID‐19 were screened; 34 received ECMO support and 31 received conventional ventilation support. Both groups had comparable characteristics at baseline in terms of age, gender, and comorbidities. Before ECMO or conventional therapy, patients in the two groups had sever acute respiratory distress syndrome with a mean partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO(2)/FiO(2)) ratio of 69.6 and 75.4, respectively. At the time of reporting, patients in the ECMO had significantly lower in‐hospital mortality compared with the control group (58.8 vs. 93.5%, p = .001). CONCLUSION: ECMO is shown to decrease the mortality of extremely critical ill COVID‐19 patients compared with the conventional treatment. Although complications occurred frequently, ECMO could still be a rescue therapy for the treatment of COVID‐19 during the pandemic.

In the late December, 2019, an unprecedented outbreak of a novel infection has emerged in Wuhan, China. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was subsequently identified and rapidly led to a worldwide pandemic. Globally, as of 6:44 pm CET, 19 January 2021, there have been 94,124,612 confirmed cases of coronavirus disease 2019 (COVID- 19) , including 2,034,527 deaths, reported to WHO. 1 The majority of cases presented mild symptoms such as cough and fever, while there exists a proportion of severe or critical cases who presented, or developed to acute respiratory distress syndrome (ARDS), acute cardiac injury, shock, and multiple organ dysfunction syndrome (MODS), even death. 2, 3 In an investigation in mainland China, the Chinese Center for Disease Control and Prevention reported that among a total of 72 314 case records, 81% of them were classified as mild, however, 14% were severe and 5% were critical. 4(p314) According to the world health organization, mechanical ventilation, steroids, and some investigational treatment options, such as intravenous immunoglobulin and convalescent plasma could be considered for the management of severe and critically ill patients. 5 And extracorporeal membrane oxygenation (ECMO) is recommended as a rescue therapy for COVID-19 with refractory hypoxemia despite lung-protective ventilation. 6 However, to date, the experience of ECMO for COVID-19 is very limited. Therefore, we report a retrospective cohort study on the effect of ECMO as a rescue therapy for extremely critical COVID-19 patients during outbreak of the pandemic.

This was a retrospective study conducted in the intensive care unit (ICU) of a hospital in charge by national rescue team in Wuhan, China, the epicenter of pandemic between Jan 2020 and Mar 2020. This study was approved by the ethics committee of the Seventh Medical 

Patients were eligible for enrollment if meeting the following criteria:

(1) Laboratory confirmed COVID-19 cases tested by real-time reverse-transcriptase polymerase chain reaction assays using specimens from both the upper respiratory tract (nasopharyngeal and oropharyngeal) and lower respiratory tract (expectorated sputum, endotracheal aspirate, or bronchoalveolar lavage), according to the world health organization criteria. 5 (2) Fulfilled the Berlin definition for ARDS. 7 (3) Met ECMO initial criteria: (1) reversible respiratory failure with hypoxemia (partial pressure of arterial oxygen to the fraction of inspired oxygen (PaO 2 /FiO 2 ) ratio less than 50 mmHg for more than three hours or PaO 2 /FiO 2 ratio less than 80 mmHg for more than 6 h; (2) Arterial blood pH less than 7.25 with a partial pressure of arterial carbon dioxide (PaCO 2 ) of at least 60 mmHg for more than 6 h with respiratory rate more than 35 breaths per minute;

(3) Plateau pressure more than 30-35 cmH 2 Table 1 shows the demographic characteristics of these patients at baseline. There were no statistically significant differences in the main clinical characteristics of patients between the two groups, including age, gender, and comorbidities (p > .05, respectively). All included patients in the two groups had severe ARDS with a mean PaO 2 /FiO 2 ratio of 69.6 and 79.4, respectively.

Both groups had similar plateau pressure, while patients in the control group had significantly lower PEEP. There were no significant differences in PaO 2 /FiO 2 ratio and PaCO 2 between the two groups.

In the ECMO group, 28 The blood gas analysis and ventilatory settings data before ECMO and conventional ventilation between the two groups are shown in Table 2 , both groups had similar modes of ventilation. Note: Data are presented as numbers (%).

Abbreviations: AC, assisted-control ventilation; APRV, airway pressure release ventilation; COVID-19, coronavirus disease 2019; CRRT, continuous renal replacement therapy; ECMO, extracorporeal membrane oxygenation; PaO 2 /FiO 2 , arterial oxygen tension to inspired oxygen fraction ratio; PEEP, positive end-expiratory pressure; PaCO 2 , partial pressure of arterial carbon dioxide; PCV, pressure-controlled ventilation; PRVC, pressure-regulatory volume control ventilation; VCV, volume-controlled ventilation. a Data on plateau pressure was missing for six patients in the ECMO group and 11 in the control group.

LI ET AL.

| 3557 older age, 21 and a higher percentage of men and a majority of patients with comorbidities were observed in several studies 2,3(p2), [21] [22] [23] In our study, the baseline characteristics of the two groups were comparable in terms of age, gender, and comorbidities, which may reduce the confounders of the study, although other confounders may still exist, such as the body mass index of the patients. In addition, for patients who received ECMO support, the sequential organ failure assessment scores and lung injury scores, ICU stay, and duration of mechanical ventilation probably contribute to the mortality. Besides, the results of the CESAR trial further suggest that referral and transfer to an ECMO center are associated with a reduction in mortality. 18 In our study, VV ECMO was the most frequently used mode in patients with COVID-19 due to its advantages of avoiding carotid cannulation and less vascular complications over VA ECMO. performed. Generally, the application of antibiotic prophylaxis is in the judgement of the physicians based on the patients' condition. 31 There are some limitations in our study: (1) First, single-center study in Chinese patients and nonrandom; (2) Second, the sample in our study was small. (3) Third, limited number of variables were collected in the context of pandemic outbreak when clinicians were not able to collect the detailed data of parameters for each patient. (4) Fourth, follow-up time of our study was short, some outcomes could not be observed. In spite of these limitations, this study still provides promise and meaningfulness to extremely critical patients with COVID-19.

In summary, the present retrospective cohort study provided evidence to suggest that, in extremely critical COVID-19 patients, the survival rate in the ECMO group was superior compared with that in the conventional ventilation group. Critically ill patients with COVID-19 appear to develop MODS and shock, 3 many factors could affect the outcomes. Whether ECMO has a role in those patients with very severe condition is still difficult to conclude due to limited experience worldwide. Understanding the risk-to-benefit ratio of performing ECMO in the clinical settings is essential. 32 Generally, our study showed that ECMO might be a rescue therapy for extremely critical COVID-19 patients.

This study was supported by the grants of Beijing health and health science and technology achievements and appropriate technology promotion project (2018-TG-49) and the capital health research and development of special (2020-2-5093).

World Health Organization. WHO coronavirus disease (COVID-19) dashboard

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Clinical characteristics of coronavirus disease 2019 in China

Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease control and prevention

Report of the WHO-China Joint Mission on coronavirus disease (COVID-19)

Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected: interim guidance

Acute respiratory distress syndrome: the Berlin Definition

Guidelines for adult respiratory failure

A Weaning Protocol for Venovenous Extracorporeal Membrane Oxygenation With a Review of the Literature

Beneficial effect of Arbidol in the management of COVID-19 infection

Use of repurposed and adjuvant drugs in hospital patients with COVID-19: multinational network cohort study

Mortality rates for patients with acute lung injury/ARDS have decreased over time

Prognosis when using extracorporeal membrane oxygenation (ECMO) for critically ill COVID-19 patients in China: a retrospective case series

Extracorporeal membrane oxygenation for coronavirus disease 2019-induced acute respiratory distress syndrome: a multicenter descriptive study

Extracorporeal membrane oxygenation for critically ill patients with coronavirusassociated disease 2019: an updated perspective of the European experience

Full COVID-19 registry dashboard

Extracorporeal membrane oxygenation in severe influenza infection with respiratory failure: a systematic review and meta-analysis

Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Extracorporeal membrane oxygenation for severe Middle East respiratory syndrome coronavirus

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region

Planning and provision of ECMO services for severe ARDS during the COVID-19 pandemic and other outbreaks of emerging infectious diseases

COVID-19 pneumonia: different respiratory treatments for different phenotypes?

EMPROVING outcomes: evaluating the effect of an ultralung protective strategy for patients with ARDS treated with ECMO

Higher vs lower positive endexpiratory pressure in patients with acute lung injury and acute respiratory distress syndrome: systematic review and metaanalysis

Prone position in intubated, mechanically ventilated patients with COVID-19: a multi-centric study of more than 1000 patients

Prone positioning in intubated and mechanically ventilated patients with SARS-CoV-2

Extracorporeal Life Support Organization Registry International Report

Extracorporeal membrane oxygenation-hemostatic complications

Infections during extracorporeal membrane oxygenation: epidemiology, risk factors, pathogenesis and prevention

Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area

Extracorporeal membrane oxygenation (ECMO) for critically ill patients with coronavirus disease 2019 (COVID-19): A retrospective cohort study

The authors declare that there are no conflict of interests.

This study was approved by the ethics committee of the Seventh Medical Center of PLA general hospital (Beijing, China) (IRB No: 2020-023).

http://orcid.org/0000-0003-4944-1432